The Latest Breaking News from Exelixis

Exelixis Inc. (NASDAQ:EXEL) on Monday reported its first quarter of 2025 adjusted earnings of 75 cents per share, compared to 85 cents a year ago, beating the consensus of 56 cents.

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong stock performance. With a dedicated focus on cancer treatment innovation and an expanding market footprint, could EXEL be the next biotech stock to add to your portfolio? Read on to find out….

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

Here's a roundup of top developments in the biotech space over the last 24 hours:

Exelixis Inc (NASDAQ:EXEL) and BioInvent International AB (OTC:BOVNF) have entered into an option and license agreement focused on identifying and developing novel antibodies for use in immuno-oncology therapeutics.  Exelixis will pay BioInvent an upfront fee of $25 million in exchange for rights to select three targets identified using BioInvent's proprietary F.I.R.S.T platform and n-CoDeR library. …

Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by 85.71%, reporting an EPS of $0.26 versus an estimate of $0.14.

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus atezolizumab versus sorafenib in untreated hepatocellular carcinoma (HCC).

The United States economy is growing strongly, outperforming other developed economies. Furthermore, analysts believe the country is well-positioned to weather economic challenges created by the Russia-Ukraine war. So, we think that growth stocks Vertex Pharmaceuticals (VRTX), Fair Isaac (FICO), Ralph Lauren (RL), and Exelixis (EXEL), which have outpaced the broader…

Biopharma stocks have been trading at lower valuations because of uncertainties surrounding drug-pricing reform, regulatory surprises, and COVID-19. However, the biopharma industry is expected to grow in the coming years. Given the bullish analysts’ sentiment around the sector, biopharma stocks Gilead (GILD) and Exelixis (EXEL), which look undervalued at their…